These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37259100)

  • 1. Chemoradiation for oesophageal cancer: the choice of treatment modality.
    Kitti PM; Faltinova M; Kauppi J; Räsänen J; Saarto T; Seppälä T; Anttonen AM
    Radiat Oncol; 2023 May; 18(1):93. PubMed ID: 37259100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus.
    Münch S; Pigorsch SU; Devečka M; Dapper H; Feith M; Friess H; Weichert W; Jesinghaus M; Braren R; Combs SE; Habermehl D
    Radiat Oncol; 2019 Apr; 14(1):66. PubMed ID: 30992022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure.
    Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
    Strahlenther Onkol; 2018 Feb; 194(2):116-124. PubMed ID: 28916906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: A phase II random.
    Qian D; Chen X; Shang X; Wang Y; Tang P; Han D; Jiang H; Chen C; Zhao G; Zhou D; Cao F; Er P; Zhang W; Li X; Zhang T; Zhang B; Guan Y; Wang J; Yuan Z; Yu Z; Wang P; Pang Q
    Radiother Oncol; 2022 Sep; 174():1-7. PubMed ID: 35764191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current optimal multimodality treatments for oesophageal squamous-cell carcinoma: A systematic review and meta-analysis.
    Li F; Ding N; Zhao Y; Yuan L; Mao Y
    Int J Surg; 2018 Dec; 60():88-100. PubMed ID: 30389537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
    Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
    Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemoradiotherapy followed by oesophagectomy may be the optimal treatment option for lower thoracic oesophageal cancer with supraclavicular lymph node metastasis: An inverse probability of treatment-weighted analysis of SEER database.
    Chang X; Liu J; Zhao Y; Shi A; Yu H; Yu R; Wang W
    J Med Imaging Radiat Oncol; 2023 Sep; 67(6):676-683. PubMed ID: 37452459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of Care and Outcomes of Elderly Esophageal Cancer Patients Not Meeting Age-based Criteria of the CROSS Trial.
    Verma V; Haque W; Zheng D; Osayande F; Lin C
    Am J Clin Oncol; 2019 Jan; 42(1):67-74. PubMed ID: 30216194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Canadian single institution real-world experience using the CROSS trial regimen in the treatment of oesophageal and gastroesophageal junction carcinoma.
    Khalid S; Hopman WM; Virik K
    Intern Med J; 2022 Sep; 52(9):1587-1595. PubMed ID: 34139041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-treatment mortality after definitive chemoradiotherapy versus trimodality therapy for locally advanced non-small cell lung cancer.
    Haque W; Verma V; Butler EB; Teh BS; Rusthoven CG
    Lung Cancer; 2019 Jan; 127():76-83. PubMed ID: 30642556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus.
    Münch S; Pigorsch SU; Devečka M; Dapper H; Weichert W; Friess H; Braren R; Combs SE; Habermehl D
    Radiat Oncol; 2018 Aug; 13(1):139. PubMed ID: 30068371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
    Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.
    de Heer EC; Hulshoff JB; Klerk D; Burgerhof JGM; de Groot DJA; Plukker JTM; Hospers GAP
    Ann Surg Oncol; 2017 Jul; 24(7):1811-1820. PubMed ID: 28188501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoradiation versus oesophagectomy for locally advanced oesophageal cancer in Chinese patients: study protocol for a randomised controlled trial.
    Jia R; Yin W; Li S; Li R; Yang J; Shan T; Zhou D; Wang W; Wan L; Zhou F; Gao S
    Trials; 2019 Apr; 20(1):206. PubMed ID: 30971301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Application of short-course radiotherapy with total neoadjuvant therapy in the treatment of middle and low rectal cancer].
    Chen CJ; Yang CK; Jian JL; Guan S; Xie MM
    Zhonghua Yi Xue Za Zhi; 2023 Jan; 103(4):271-277. PubMed ID: 36660788
    [No Abstract]   [Full Text] [Related]  

  • 16. [Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer].
    Wu T; Wen L; Zhang J; Wu Y; Jiang Y; Chen G; Wang X; Huang S; Wan Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):59-65. PubMed ID: 30703795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical outcomes for hilar and extrahepatic cholangiocarcinoma with adjuvant, definitive, or liver transplant-based neoadjuvant chemoradiotherapy strategies: a single-center experience.
    Laughlin BS; Petersen MM; Yu NY; Anderson JD; Rule WG; Borad MJ; Aqel BA; Sonbol MB; Mathur AK; Moss AA; Bekaii-Saab TS; Ahn DH; DeWees TA; Sio TT; Ashman JB
    J Gastrointest Oncol; 2022 Feb; 13(1):288-297. PubMed ID: 35284111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage for stage comparison of recurrence patterns after definitive chemoradiotherapy or surgery for oesophageal carcinoma.
    Reid TD; Davies IL; Mason J; Roberts SA; Crosby TD; Lewis WG
    Clin Oncol (R Coll Radiol); 2012 Nov; 24(9):617-24. PubMed ID: 22386923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival after neoadjuvant chemoradiotherapy and oesophagectomy versus definitive chemoradiotherapy for patients with oesophageal squamous cell carcinoma.
    Wang BY; Wu SC; Chen HC; Hung WH; Lin CH; Huang CL; Chen HS
    Br J Surg; 2019 Feb; 106(3):255-262. PubMed ID: 30395362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.